Analysts Offer Predictions for BioLineRx Ltd.’s Q2 2024 Earnings (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRXFree Report) – Zacks Small Cap issued their Q2 2024 earnings per share estimates for BioLineRx in a research report issued on Monday, June 10th. Zacks Small Cap analyst J. Vandermosten forecasts that the biotechnology company will post earnings of ($0.01) per share for the quarter. The consensus estimate for BioLineRx’s current full-year earnings is ($0.25) per share. Zacks Small Cap also issued estimates for BioLineRx’s Q3 2024 earnings at ($0.01) EPS, Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at ($0.03) EPS and FY2025 earnings at ($0.03) EPS.

Other equities analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday, May 29th. StockNews.com raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, June 3rd.

Check Out Our Latest Stock Analysis on BLRX

BioLineRx Stock Performance

NASDAQ BLRX opened at $0.67 on Thursday. The firm has a market cap of $53.39 million, a price-to-earnings ratio of -0.88 and a beta of 1.54. The company has a quick ratio of 1.05, a current ratio of 1.14 and a debt-to-equity ratio of 0.45. The business has a 50-day moving average price of $0.67 and a 200-day moving average price of $1.10. BioLineRx has a twelve month low of $0.55 and a twelve month high of $2.53.

BioLineRx (NASDAQ:BLRXGet Free Report) last released its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.28. The company had revenue of $6.86 million for the quarter, compared to the consensus estimate of $0.34 million. During the same period in the prior year, the firm posted ($0.15) EPS.

Institutional Investors Weigh In On BioLineRx

A number of hedge funds have recently made changes to their positions in BLRX. Rathbones Group PLC purchased a new stake in shares of BioLineRx in the third quarter worth about $72,000. Allen Mooney & Barnes Investment Advisors LLC purchased a new stake in shares of BioLineRx in the third quarter worth about $46,000. B. Riley Wealth Advisors Inc. lifted its position in shares of BioLineRx by 88.5% in the third quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock worth $39,000 after buying an additional 10,000 shares in the last quarter. NorthRock Partners LLC purchased a new stake in shares of BioLineRx in the fourth quarter worth about $27,000. Finally, PVG Asset Management Corp purchased a new stake in shares of BioLineRx in the fourth quarter worth about $97,000. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Featured Articles

Earnings History and Estimates for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.